JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Edward J GaneMan-Fung YuenThomas N KakudaTetsuro OgawaYasushi TakahashiNele GoeyvaertsIsabelle Lonjon-DomanecTamisha VaughanThomas SchluepJames HamiltonEmmanuel Njumbe EdiageVera HillewaertJan SnoeysOliver LenzWillem TalloenMichael BiermerPublished in: Antiviral therapy (2022)
JNJ-73763976 and JNJ-73763924 had short plasma half-lives and exposure generally increased in a dose-proportional manner; there were no pharmacokinetic differences between Japanese and non-Japanese healthy adults. JNJ-73763989 with or without JNJ-56136379 and NA was generally safe and well tolerated.